Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus

NCT01835431 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT01835431
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01835431 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus
Lead sponsor
Novo Nordisk A/S
Phase
Phase 3
Overall status
Completed
Start date
October 17, 2013
Completion date
November 7, 2014
Enrollment
362 (actual)
Sites
73

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes, diabetes mellitus, type 1